Frontotemporal Disorders Treatment Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Japan, China, India, Australia, Brazil, Mexico, South Africa, Saudi Arabia), Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Report ID: GMI4424

Summary Methodology

Frontotemporal Disorders Treatment Market size is expected to grow significantly from 2019 to 2025.

Frontotemporal dementia usually affects the frontal and temporal lobes of the patients’ brain. In this category of dementia, there is no memory loss in early stages as seen in Alzheimer's dementia. Rather, changes in behavior, personality and social skills affects the patient’s body. Although, most of the cases are diagnosed in people between the age of 45 and 65 years, it can also affect younger people.

Global Frontotemporal Disorders Treatment Market, By Disease Type, 2018 and 2025 (USD Million)
Global Frontotemporal Disorders Treatment Market, By Disease Type, 2018 and 2025 (USD Million)

Get more details on this report - Request Free Sample PDF

Frontotemporal dementia is a less common type of disorder with distinct and heterogeneous syndromes. Frontotemporal is characterized by progressing deficits in language, functioning and behavior of the patients. Frontotemporal diseases may exhibit features similar to several other psychiatric disorders owing to its prominent behavioral characteristics. Thus, due to such factors the usage of precision medicine has highly surged. Additionally, it involves neurodegenerative disease treatment, that can be personalized according to patient’s individual pattern of genetic variability. Hence, above mentioned aspects thereby prove beneficial for the frontotemporal disorders’ treatment market growth.

Increasing incidence of dementia across the globe will accelerate the demand for frontotemporal disorders treatment drugs. Frontotemporal disorder has a social, psychological, physical, and economic impact on the patients’ health. Moreover, according to WHO 2019, worldwide approximately 50 million individuals suffer from dementia, with 10 million new cases each year. Additionally, dementia is one of the major causes of dependency and disability among elderly population base due to ageing factors. Abovementioned factors will surge the demand for frontotemporal treatment drugs across the forecast timeframe.

However, lack of awareness regarding frontotemporal treatment among population may hinder the frontotemporal disorders treatment market growth. Also, lack of approved drugs for frontotemporal disorders will further hinder market growth.

The frontotemporal disorders treatment market is fragmented into disease type, drugs and end-use. On the basis of diseases type the market is sub-segmented into behavioral variant frontotemporal dementia, primary progressive aphasia (PPA) and motor decline. Behavioral variant frontotemporal dementia segment is anticipated to witness lucrative growth during the analysis period. The symptoms for behavioral variant frontotemporal dementia include apathy, behavioral changes, disinhibition in interpersonal interactions and progressive personality. Patients with such disorders may experience changes in stereotypic behavior and dysexecutive symptoms that can severely affect individual’s health. Also, problems related to memory coupled with excessive emotions will foster the overall segmental progress.

On the basis of drug class, the frontotemporal disorders treatment market is segmented as antidepressants and antipsychotics. The antidepressant segment will grow substantially over the forecast timeline owing to increasing incidence of frontotemporal diseases over the coming years. Antidepressants are extensively used to minimize the behavioral problems associated with frontotemporal dementia. Several other type of antidepressants are widely preferred by physicians to manage patient health effectively that boosts segmental growth. Moreover, (SSRIs) selective serotonin reuptake inhibitors also proves beneficial for the treatment of frontotemporal disorders.

End-use segment is fragmented into hospitals, clinics, online pharmacy and others. Hospitals segment will witness considerable growth over the analysis timeframe. Frontotemporal disorders treatment in hospital settings helps in managing individual’s health more accurately with availability of skilled healthcare personnel. However, no specific treatments are available to completely cure the progression of frontotemporal diseases. Furthermore, doctors prescribe antidepressant medications that may help in treating the anxiety and other symptoms.

North America frontotemporal disorders treatment industry will account for lucrative revenue share by 2025 owing to rising prevalence of frontotemporal disorders in this region. Increasing awareness regarding frontotemporal disorders among Americans and rising elderly population base surges the regional growth.

Prominent industry players operating in frontotemporal disorders treatment market include Allergan, AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Mylan, Pfizer and Sanofi. Notable business players operating in this industry adopt numerous inorganic strategies to compete in the market and to have competitive edge over other players. For instance, in September 2019, Alector a clinical stage biotechnology company-initiated Phase 2 trial of AL001 in patients with frontotemporal dementia. This strategy will eventually boost the product offerings of the company.

Frontotemporal Disorders Treatment Market By Disease Type, 2014-2025 (USD Million)

  • Behavioral variant frontotemporal dementia
  • Primary progressive aphasia (PPA)
    • Semantic PPA
    • Agrammatic PPA
    • Logopenic PPA
  • Motor Decline
    • Corticobasal syndrome (CBS)
    • Progressive supranuclear palsy (PSP)

Frontotemporal Disorders Treatment Market By Drug Class, 2014-2025 (USD Million)

  • Antidepressants
  • Antipsychotics

Frontotemporal Disorders Treatment Market By End-use, 2014-2025 (USD Million)

  • Hospitals
  • Clinics
  • Online pharmacy
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

Company Profiles:

  • Allergan
  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Mylan
  • Pfizer
  • Sanofi


What Information does this report contain?

Historical data coverage: 2016 to 2020; Growth Projections: 2021 to 2027.
Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
6-7 year performance forecasts: major segments covering applications, top products and geographies.
Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Customize this Report

Pre Book Now

Need a Discount? Get in touch with us for special pricing

Request Discount

Our Market Research Reports Include:

  • Market snapshot
  • Market Segmentation
  • Value Chain Analysis
  • Growth Dynamics
  • Potential Market Opportunities
  • Regulatory Overview
  • Technology Evolution
  • Innovation & Sustainability

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X